Trial Profile

Phase I Study of Nilotinib Given With Radiation For Patients With High Risk Chordoma.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nilotinib (Primary)
Indications Chordoma
Focus Adverse reactions

Most Recent Events

31 May 2020 Results of phase I study of nilotinib plus radiation (RT) in high-risk chordoma presented at the 56th Annual Meeting of the American Society of Clinical Oncology
03 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2025.
11 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com